Alkame Holdings Reports 2022 Results
Valued shareholders,
We would like to take this opportunity to provide a long overdue update for the close of 2022.
Alkame Holdings Inc. reported revenues of
Alkame revenues for co-packing fees were
Last year Alkame Holdings Inc. wiped out
Key Financials:
- 2022 revenues up
19% year over year - 2022 liabilities down over
to$1 million - down$5.1 m il17% year over year. - 2022 co-pack revenues were
.$658,000 - 2023 projected co-pack revenues
+.$900,000 - 2023 projected Maury Island and Quinn's revenues -
+.$350,000
"We are expecting co-packing revenues of over
About Alkame Holdings, Inc.
Alkame Holdings, Inc. is a publicly traded diversified holding company. The Company's wholly owned subsidiaries include proprietary water technology with several unique properties, food and beverage manufacturing and co-packing, CBD /Hemp food and beverage manufacturing, and utilizes their enhanced water technology whenever applicable, along with several company owned developed and acquired consumer brands. The organization is diligently building a strong foundation through the launch and acquisition of appropriate business assets, and by pursuing multiple applications by placement into several emerging business sectors, such as consumer bottled water and RTD products, household pet products, and many other various water-based treatment solutions to both new and existing business platforms. For more information, visit www.alkameholdingsinc.com.
Alkame Holdings, Inc. Investor Relations
Website: www.alkameholdingsinc.com
Email: info@alkameholdingsinc.com
Disclaimer/Safe Harbor: This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that Alkame will achieve significant sales, the failure to meet schedule or performance requirements of the Company's contracts, the Company's liquidity position, the Company's ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
View original content:https://www.prnewswire.com/news-releases/alkame-holdings-reports-2022-results-301857153.html
SOURCE Alkame Holdings